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Abstract
Purpose of Review This review will examine the implications for perioperative management of new hypertension guidelines and
place these in the context of findings from recent large observational studies.
Recent Findings Recent hypertension guidelines highlight the role of ambulatory blood pressure measurement with the impli-
cation that isolated preoperative blood pressure measurements are of limited value. There is emerging evidence from large
observational studies that both preoperative and intraoperative hypotension are associated with increased risk. It is not clear if
this is a particular concern for hypertensive patients.
Summary Assessment of the hypertensive surgical patient should include blood pressure measurements taken using the correct
technique. Preoperative blood pressures of less than 180/100 mmHg are not grounds for deferring surgery in the absence of active
comorbid disease. Evidence to guide the perioperative management of patients with higher pressures is scanty and decisions
should be made on a case-by-case basis.
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Introduction
Hypertension is common. In 2011, 31% of men and 28% of
women in the UK were classified as hypertensive, defined as
having a blood pressure greater than 140/90 mmHg [1]. The
burden of hypertension is greater in older people with 72.6%
of people aged over 75 years considered to be hypertensive.
Raised blood pressure is associated with life-threatening co-
morbidities including ischaemic heart disease, heart failure,
renal impairment, and cerebrovascular disease. Whilst the in-
cidence of these complications can be reduced by effective
blood pressure management, achieving good blood pressure
control at a population level remains challenging. Of the
29.5% of adults considered to be hypertensive in 2011, only
10.4% had adequate blood pressure control, with 6.4% having
inadequate blood pressure control despite treatment and
12.7% with untreated hypertension. Hypertension is relevant
to the anaesthetist for a number of reasons including the asso-
ciated target organ damage, the possibility of the patient hav-
ing a serious condition causing secondary hypertension, the
question of the best management of blood pressure in hyper-
tensives in the perioperative period, and the broader responsi-
bility on all healthcare staff to ensure that newly diagnosed
and poorly controlled hypertension is adequately treated.
The Definition and Diagnosis of Hypertension
Threshold blood pressures for the diagnosis of hypertension
are based on the association between a given blood pressure
and comorbid disease such as ischaemic heart disease or renal
failure. There is a continuum of risk, higher blood pressures
being associated with a higher incidence of complications.
Severe hypertension, for example a systolic blood pressure
of greater than 180 mmHg is uncommon but carries very
considerable risks for the patient. Lesser degrees of raised
blood pressure such as a blood pressure of 140–150 mmHg
systolic are much more common and, whilst they carry less
risk for the individual patient, are responsible for a great deal
of the population burden of cardiovascular disease. The defi-
nition and categorisation of hypertension rests on striking a
balance between the prevention of such cardiovascular disease
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and the requirement to treat a large proportion the population
with antihypertensivemedications [2]. Various national guide-
lines identify cut-off values for hypertension at similar but not
identical blood pressure levels. In the USA, the Eighth Joint
National Committee on the Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC8) recommends
treatment for raised blood pressure for patients aged 60 years
or older without diabetes or chronic kidney disease with a goal
of reducing the blood pressure to less than 150 mmHg systolic
and 90 mmHg diastolic [3]. For patients aged under 60 years,
the targets are a systolic blood pressure of less than
140 mmHg and a diastolic pressure of less than 90 mmHg.
These targets are less demanding than in the previous JNC7
guideline which recommended treating blood pressure to tar-
get of less than 140/90 mmHg and to less than 130/80 mmHg
in patients with diabetes or renal disease [4]. The UKNational
Institute for Health Care and Clinical Excellence (NICE) 2011
guidance defines normotension as a blood pressure of less
than 140/90 mmHg when the measurements are made in the
clinical setting [5••]. The guidance categorises hypertension as
stage I (a clinic blood pressure of 140/90 to 160/90 mmHg or
an ambulatory blood pressure of 135/85 to 150/95 mmHg)
and stage II (a clinic blood pressure of 160/90 to 180/
109 mmHg or an ambulatory blood pressure of greater than
150/95 mmHg). The most recent NICE guidelines added a
category of severe hypertension with a clinic systolic blood
pressure of 180 mmHg or greater or a diastolic blood pressure
of 110 mmHg or greater. Whilst a diagnosis of stage I or stage
II hypertension requires multiple measurements on different
occasions, treatment may be initiated at once in patients with
severe hypertension. These guidelines also place emphasis on
the use of blood pressure monitoring outside of the clinic. The
guidance identifies ambulatory monitoring as the preferred
method for BP recording to diagnose hypertension with home
blood pressure readings taken by the patient as the second
choice if ambulatory monitoring is not available. In contrast,
the 2013 European Society of Hypertension and European
Society of Hypertension/European Society of Cardiology
guidance lists ambulatory and home blood pressure monitor-
ing as additional tests to be used if required [6].
Whichever guidelines are being applied, it is essential that
appropriate technique is used when measuring the blood pres-
sure. The patient should be sitting quietly with the arm sup-
ported at heart level. The patient should not be engaging in
conversation. An appropriate size cuff should be used. If an
automated device is used, it should conform to the appropriate
national standards [7]. The pulse should be palpated before the
reading is taken and manual measurements made if the patient
is in an irregular rhythm such as atrial fibrillation. If the BP is
elevated, a second reading should be taken at least a minute
after the first reading. If there is a marked discrepancy between
these two blood pressure readings, a third reading should be
taken again after a suitable interval [6]. These standards are
often not met in the preassessment clinic or on the ward before
surgery and if a patient being assessed for surgery is found to
have elevated blood pressure, it is appropriate to repeat the
blood pressure readings ensuring that the correct technique is
used.
Blood pressures recorded in patients coming to hospital for
elective surgery are often elevated. It would not be appropriate
to diagnose new or poorly controlled hypertension on the
basis of blood pressure recordings from the preassessment
clinic. However, the effect of the medical setting is related to
the true blood pressure with “white-coat” hypertension being
seen in 55% of people with grade 1 hypertension but only
about 10% of people with severe hypertension [8]. Patients
who have markedly elevated blood pressures in the
preassessment clinic are more likely to have persistently raised
blood pressure and should be referred to their general practi-
tioner or community physician for further follow-up.
Hypertension is of concern because of the extensive dam-
age that it can cause throughout the body. Target organ dam-
age in the heart may be manifest as left ventricular hypertro-
phy, diastolic dysfunction, heart failure, microvascular dis-
ease, and atherosclerotic coronary artery disease [2]. The brain
may be affected by lacuna infarcts and impaired cognition.
Hypertension is a major cause of stroke and severe hyperten-
sion may produce hypertensive encephalopathy. The vascular
damage caused by hypertension is directly visible in the eye as
hypertensive retinopathy. The kidneys may be affected by
glomerular injury, glomerulosclerosis, renal tubular ischae-
mia, and end-stage renal failure. The wider circulation may
be affected by peripheral arterial disease which in the worst
cases can lead to critical limb ischaemia and limb loss. The
assessment of the presence and severity of target organ dam-
age is an important aspect of the preoperative assessment of
the hypertensive patient. The presence of such damage is an
indicator of the severity of hypertension. The patient who
presents with both raised blood pressure and its sequelae is
unlikely to have white coat hypertension. Investigations of the
patient presenting with raised blood pressure should include
full blood count; serum sodium, potassium, and creatinine;
plasma glucose; urine testing for microalbuminuria; and a
12-lead ECG [5••]. Comprehensive assessment of the hyper-
tensive patient also includes measurement of serum uric acid,
cholesterol, and high-density and low-density lipoprotein.
Performing these additional tests is helpful if the patient is to
be referred on for further assessment of their blood pressure.
The Aetiology of Hypertension
Blood pressure is regulated by a number of integrated cardio-
vascular control systems. The immediate control of blood
pressure over the course of 10 to 20 s is through changes in
heart rate and vascular tone in response to blood pressure
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changes sensed by the carotid and aortic baroreceptors.
Control of blood pressure over minutes to hours is through
the regulation of circulating volume. Low-pressure receptors
in the atria and great veins regulate the release of antidiuretic
hormone and atrial natriuretic factor. The long-term control of
the “set-point” around which an individual’s blood pressure is
regulated is through the renin-angiotensin-aldosterone system
(RAAS) which controls natriuresis and through this, diuresis
[9]. The RAAS has a high gain. That is to say small changes in
blood pressure produce a vigorous response and return the
blood pressure to its set point.
In primary hypertension, the set point for blood pressure is
elevated. Primary hypertension was previously known as es-
sential hypertension and has been renamed to better reflect our
incomplete understanding of the mechanisms of this change. It
is thought that primary hypertension is due to the interaction
of genetic and environmental factors [10]. Genetic variation in
the sodium homeostasis and the RAAS is thought to have a
significant role. Environmental factors include alcohol con-
sumption, psychological stress, high sodium intake, low po-
tassium intake, and low calcium intake.
It has been proposed plasma renin activity (PRA) may be
useful to guide the treatment of hypertensive patients. This
approach suggests that patients with low-renin, volume-
dependant hypertension (PRA < 0.65 ng/ml−1/h−1) should
be treated with an “anti-volume” drug such as a diuretic
whereas those with high-renin vasoconstriction hypertension
(PRA > 0.65 ng ml−1 h−1) should be managed with an an-
tagonist of the renin-angiotensin system such as an ACE
inhibitor [11]. These recommendations have not been
adopted into the various national and international guidelines
on hypertension but PRA-guided therapy remains an area of
active research. The thesis carries the implication for intra-
operative care that the subset of patients with “pure” high-
renin hypertension will have marked arteriolar vasoconstric-
tion and may be particularly sensitive to the vasodilating
effects of anaesthetic agents.
Approximately 95% of patients presenting with raised
blood pressure will be considered to have primary hyperten-
sion. In a small number of patients, it will be possible to
identify an underlying pathology. These patients are consid-
ered to have secondary hypertension and are a particular con-
cern because many of the conditions underlying secondary
hypertension have pernicious effects both on the long-term
health of the patient and the well-being of the patient during
surgery and anaesthesia. Younger patients with raised blood
pressure may have secondary hypertension and any hyperten-
sion in an individual aged less than 20 years or raised blood
pressure requiring treatment in an individual younger than
30 years should prompt a search for the causes of secondary
hypertension. A sudden onset or worsening of hypertension or
hypotension resistant to treatment with three or more drugs
should prompt consideration of secondary hypertension.
The clinician should be alert for the symptoms and signs of
diseases that can cause raised blood pressure. Elevated serum
creatinine, the presence of proteinuria or haematuria, polycys-
tic kidneys identified on imaging, or the presence of a murmur
or angiographic evidence of renal artery stenosis should lead
to consideration of renal hypertension. Delayed or absent fem-
oral pulses and an audible murmur may indicate the presence
of aortic coarctation. The hypertensive patient who has
hypokalaemia with an increased plasma sodium may have
Conn’s syndrome due to a mineralocorticoid-secreting tu-
mour. The signs of Cushing’s syndrome should prompt con-
sideration of this diagnosis. The patient who has the stigmata
of neurofibromatosismay have an associated pheochromocytoma.
The Treatment of Hypertension
The treatment of hypertension is directed towards lowering
blood pressure in order to prevent or reduce end organ damage
and the risk of premature death or disability. The management
of the patient should be set in the context of a broader estima-
tion of long-term cardiovascular risk. Where there is a history
of previous cardiovascular disease, the patient should be re-
ceiving appropriate cardiovascular secondary prevention such
as antiplatelet agents and statins [12, 13].
Care should include lifestyle advice to the patient on issues
including regular exercise, weight loss, avoiding excess alco-
hol consumption, and strategies to reduce psychological stress
where possible. In some cases, these changes may be suffi-
cient to reduce the blood pressure; however, many patients
will require pharmacological treatment.
The commonly used antihypertensive drugs may be divid-
ed into three broad classes, those that increase salt and water
excretion, those that act on the RAAS, and vasodilators that
increase salt and water excretion through mechanisms other
than the RAAS [14, 15].
Drugs Acting on the RAAS
Drugs which act upon the RAAS reduce the production of
angiotensin II or inhibit its action. Angiotensin II is produced
by the action of angiotensin-converting enzyme on angioten-
sin I. Angiotensin II has multiple actions. It acts on AT1 re-
ceptors increasing arteriolar tone and systemic vascular resis-
tance. It increases sympathetic nervous system activation. Its
hormonal effects include increased pituitary secretion of
antidiuretic hormone and ACTH and increased secretion of
aldosterone by the adrenal cortex. Drugs which interfere with
these actions reduce systemic vascular resistance and salt and
water retention, thus lowering blood pressure.
The angiotensin-converting enzyme inhibitors (ACEI) act
by reducing the conversion of angiotensin I to angiotensin II
in the lungs. This class of drugs includes the oral drugs
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captopril, enalapril, ramipril, perindopril, and lisinopril.
Enalaprilat is the active form of enalapril and is administered
intravenously. ACEI are first-line agents for the treatment of
primary hypertension in patients aged less than 55 years.
The angiotensin receptor antagonist (ARA) drugs act on
AT1 receptors and antagonise the action of angiotensin II.
Losartan and valsartan are competitive antagonists whilst
candesartan and telmisartan bind irreversibly with the AT1
receptor. The ARAs do not inhibit bradykinin metabolism
and because of this, ARAs are less likely than ACEI to cause
a chronic cough. They also have the potential merit of
blocking the action of angiotensin II produced by pathways
other than angiotensin-converting enzyme such as that are
produced by the action of chymase in the kidney.
Both ACEI and ARAs can produce relative hypovolaemia
and there are reports of an increased incidence of hypotension
with induction of anaesthesia with both these classes of drug.
This is said to be particularly marked with a combination of
ARAs and diuretics [16•, 17]. Many units have local guide-
lines recommending the omission of one or two doses of
ACEI or ARAs prior to induction of anaesthesia. Doing so
does not appear to be associated with an increased risk of
postoperative hypertension [18].
Aliskiren is a direct renin inhibitor which is administered
orally and has a place in the treatment of hypertension refrac-
tory to management with other medications. It has a long
elimination half-life of 24 to 40 h and there are concerns that
it may be associated with refractory hypotension following
induction of anaesthesia. However, the data to support this
are limited [19].
Beta-blockers are no longer considered to be first-line an-
tihypertensive agents unless also being administered for other
indications such as secondary prevention following myocar-
dial infarction. They act to inhibit catecholamines at G
protein-coupled β-adenoreceptors and reduce blood pressure
through multiple mechanisms. The blockade of cardiac β-1
receptors reduces heart rate and beta-blockade also reduces
myocardial contractility. Blockade of β-receptors in the
juxtaglomerular apparatus reduces renin secretion and thus
salt and water retention.
Vasodilator Antihypertensive Drugs
Calcium Channel Blockers
Calcium channel blockers (CCBs) are first-line treatment for
primary hypertension in patients aged over 55 years and in
black patients of African or Caribbean origin. CCBs act on L-
type calcium channels in vascular smooth muscle and the
heart. Those with a greater affinity for the myocardium, for
example verapamil and diltiazem, have a role in the manage-
ment of tachyarrhythmias and angina. CCBs with a particular
affinity for vascular smooth muscle, such as nifedipine,
produce vasodilatation and are favoured for the management
of hypertension. It should be noted that nifedipine can cause
significant vasodilatation with a reflex tachycardia. There has
long been the concern that sublingual nifedipine can produce
dramatic reductions in blood pressure and myocardial ischae-
mia in elderly patients [20]. CCBs are generally continued
through the perioperative period. There is little or no evidence
to support initiating CCBs in the perioperative period for myo-
cardial protection unless there is a clear medical indication for
their prescription.
Alpha-1 Receptor Antagonists
Alpha-1 blockers act at post-ganglionic α-1 Gq protein-
coupled receptors causing smooth muscle relaxation and va-
sodilatation. Selective alpha-1 blockers such as doxazosin are
used in the management of hypertension that is refractory to
treatment with first-line drugs alone. Nonselective alpha
blockers act at both α-1 and α-2 receptors. Blockade of pre-
synaptic alpha-2 receptors increases norepinephrine release
and may cause tachycardia. However, nonselective alpha
blockers such as phenoxybenzamine and phentolamine have
a place in the management of pheochromocytoma. Labetalol
acts as an antagonist atα-1 receptors and is also a nonselective
β-receptor antagonist; thus, it lowers blood pressure by caus-
ing vasodilatation and can counteract the reflex tachycardia
that may result from a fall in blood pressure produced by α-1
receptor blockade and vasodilation.
Diuretics
Thiazide (bendrofluazide, hydrochlorothiazide) and thiazide-
like diuretics (chlorthalidone, indapamide) are used to treat
hypertension in patients intolerant of CCBs and in those
who have or are at risk of heart failure. They also are widely
prescribed as second-line drugs in patients who have not
responded to initial pharmacological treatment. They inhibit
sodium and chloride reabsorption in the proximal part of the
distal tubular and so produce diuresis. They also act directly
on vascular smooth muscle opening calcium-activated potas-
sium channels and reducing systemic vascular resistance.
The side effects of thiazide diuretics are well known and
have direct relevance to perioperative management.
Patients taking these drugs may suffer from hypokalaemia,
hyponatraemia, hypercalcaemia, hypomagnesaemia,
hyperuricaemia, hypercholesterolaemia, hypoglycaemia,
and hypokalaemia alkalosis.
Aldosterone antagonists such as spironolactone are used as
fourth-line agents in the treatment of hypertension. The loop
diuretics have a place in the management of resistant hyper-
tension in patients with heart failure or chronic kidney disease.
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Other Antihypertensive Drugs
Direct acting vasodilators include hydralazine and minoxidil.
Vasodilator drugs cause side effects including headache, fluid
retention, and oedema and are generally poorly tolerated.
However, hydralazine has a place in the management of pre-
eclampsia.
Centrally acting drugs such as clonidine, methyldopa, and
monondinine are associated with significant adverse effects
and are reserved for refractory hypertension. Again, methyl-
dopa has a specific place for the management of hypertension
in pregnancy.
The Association Between Preoperative Blood
Pressure and Perioperative Risk
Historically, concerns about the care of the hypertensive pa-
tient have focused on the perceived risks of anaesthesia and
surgery and the appropriateness of deferring surgery to allow
the blood pressure to be treated and reduced.
The risks of anaesthesia and surgery in hypertensive pa-
tients were highlighted in a case series published in 1929
which described the outcomes of a series of patients with
cardiac disease who underwent anaesthesia and surgery at
the Massachusetts General Hospital between 1917 and 1927
[21]. Twenty-four of the 75 patients with atherosclerotic or
hypertensive heart disease died, one half succumbing to heart
failure. The ensuing decades brought an increasing under-
standing of the health risks posed by high blood pressure
and the introduction of the first effective treatments for hyper-
tension. A series of studies published in the early 1970s sug-
gested that untreated hypertensives undergoing anaesthesia
and surgery displayed greater cardiovascular instability and
were at greater risk of myocardial ischaemia than those receiv-
ing treatment for hypertension [22–24]. On the basis of these
findings, it became a recommended practice that patients with
poorly controlled or untreated hypertension should have their
blood pressure brought under control before anaesthesia and
surgery. These studies were conducted on a relatively small
number of patients. The definition of hypertension has been
revised several times since this work was done with the blood
pressure thresholds that define hypertension being revised
downwards repeatedly. Hence, it is not appropriate to use
the findings of these studies to inform practice in patients with
moderately raised blood pressure, that is with blood pressures
consistent with stage 1 or stage 2 hypertension [25].
Studies conducted over the past 20 years suggest that mild-
to-moderate preoperative hypertension is not a major risk fac-
tor for complications [26–29]. Whilst a number of studies
have shown a univariate association between increased blood
pressure and perioperative cardiac complications, this associ-
ation tends to disappear when adjustment is made for major
cardiac risk factors such as heart failure and previous myocar-
dial infarction. (It should of course be noted that these repre-
sent the sequelae of hypertension in many patients.) The
American College of Cardiology/American Heart
Association Guidelines on Perioperative Evaluation and
Care for Non-Cardiac Surgery do not identify hypertension
as a risk factor that should lead to the deferring or cancelling
surgery [30]. The European Society of Cardiology/European
Society of Anaesthesiology guidelines take a similar position
[31]. This is not to say that preoperative hypertension should
be disregarded completely as a cause for concern in perioper-
ative management. There is evidence that these patients are
more prone to perioperative myocardial ischaemia [32]. The
European guidelines highlight the fact that patients may dis-
play increased cardiovascular instability particularly at induc-
tion of anaesthesia. The anaesthetist should be aware of these
concerns and manage the patient accordingly.
Evidence is scanty regarding the management of patients
who are present for surgery and are found to have markedly
raised blood pressure on repeated measurement. Patients pre-
senting in primary care with severe hypertension would be
considered for the immediate initiation of antihypertensive
treatment without further clinic visits. The European guide-
lines suggest that delaying surgery for further assessment may
be considered in patients who are found to have blood pres-
sure readings consistently greater than 180 mmHg systolic or
110 mmHg diastolic. [31] This decision should be made on a
case-by-case basis taking into account the relative consider-
ations of cardiovascular risk and the potential harm from
delaying surgery.
Data are now emerging from large databases that may be
relevant to this discussion. A recent analysis of a large UK
primary care database of over quarter of a million patients
found an association between postoperative mortality and
elevated diastolic pressure [33••]. Elevated diastolic, but
not systolic, pressure was found to be associated with in-
creased postoperative mortality with the association begin-
ning at diastolic blood pressures of greater than 90 mmHg.
These findings are striking given the fact that in the nonsur-
gical setting, diastolic hypertension is a more potent cardio-
vascular risk factor than systolic hypertension up to age
50 years. Above this age threshold systolic blood pressure
is the more potent risk factor [34]. An important and novel
additional finding from this study was that in patients aged
over 65 years, preoperative diastolic hypotension was asso-
ciated with a risk of postoperative death and that this asso-
ciation persisted for an adjustment for other risk factors.
This finding is biologically plausible in that diastolic pres-
sure is one of the key determinants of mean arterial pressure
which in turn is related to organ perfusion. The importance
of these findings in the broader context of preoperative as-
sessment is an area of active debate and is potentially rele-
vant to intraoperative management.
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The Intraoperative Management
of the Hypertensive Patient
Whilst the primary focus of this review is the preoperative
management of the hypertensive surgical patient, this inevita-
bly has a bearing on intraoperative care. It has been noted
above and is highlighted in the most recent European guide-
lines that hypertensive patients may display greater cardiovas-
cular lability during surgery with increases in blood pressure
of 20 to 30 mmHg and heart rate of 15 to 20 bpm at induction
of anaesthesia and a risk of hypotension in the intraoperative
period [35]. A number of large observational studies have now
demonstrated an association between intraoperative hypoten-
sion and adverse outcome. A study of over 33,000 patients
showed an association between a mean arterial pressure less
than 55 mmHg and myocardial and renal injury with a linear
relationship between the duration of hypotension on the inci-
dence of organ injury [36]. A study of over 24,000 operations
conducted in six hospitals showed increased 30-day mortality
in patients in the lowest quartile of systolic, mean, and diastol-
ic pressure [37••].
These findings are striking especially when set in the con-
text of the report referenced above an association between
preoperative diastolic hypotension and adverse outcome.
The concept of autoregulation of organ perfusion is a well-
established tenant of physiology [38]. Put simply, the circula-
tion functions as a constant pressure (mean arterial pressure)
variable flow system with the flow to individual organs being
regulated by arteriolar vascular tone and flow at rest being
held constant over a relatively wide range of blood pressure.
It has been demonstrated that this autoregulatory rangemay be
shifted to the right (higher blood pressures) in hypertensive
individuals. Thus, it may be that patients with hypertension
are less tolerant of periods of low blood pressure than their
normotensive peers [39]. Randomised controlled trials of the
optimal management of intraoperative blood pressure in hy-
pertensive and normotensive patients are lacking but the ob-
servational data discussed above and our understanding of
cardiovascular physiology suggested that care should be taken
to avoid periods of intraoperative hypotension relative to the
awake blood pressure, especially in elderly patients.
Conclusions: Broader Responsibilities
The reader will have gathered from this review that much of
the advice and guidance around the pre-and perioperative
management of the hypertensive patient are based on epide-
miological data rather than randomised controlled trials and
that the care of hypertensive individuals requires the combi-
nation of an understanding of the evidence including its
strengths and limitations and pragmatic clinical judgement
on the part of the anaesthetist. It is important to remember that
outside of the surgical setting, the evidence for treating raised
blood pressure is robust and that doing so can spare the patient
the life-changing crisis of a stroke or myocardial infarction.
Thus, whilst it may not be appropriate to defer anaesthesia and
surgery in a patient with mild or moderate hypertension, the
anaesthetist shares a responsibility with other doctors to en-
sure that the patient found to have persistently elevated blood
pressure during preassessment is referred for further blood
pressure readings and appropriate management either before
or after surgery as appropriate.
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